华恒生物
(688639)
| 流通市值：46.92亿 | | | 总市值：46.92亿 |
| 流通股本：2.50亿 | | | 总股本：2.50亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,632,264,595.09 | 771,264,504.42 | 2,861,841,123.69 | 2,193,542,266.71 |
| 营业收入 | 1,632,264,595.09 | 771,264,504.42 | 2,861,841,123.69 | 2,193,542,266.71 |
| 二、营业总成本 | 1,541,796,088.26 | 736,379,623.79 | 2,744,165,757.74 | 2,022,179,740.12 |
| 营业成本 | 1,247,208,485.85 | 609,588,465.23 | 2,253,217,750.21 | 1,676,957,842.01 |
| 税金及附加 | 9,389,884.94 | 4,160,733.69 | 16,525,279.59 | 12,570,961.15 |
| 销售费用 | 32,179,946.38 | 14,194,614.27 | 71,457,794.64 | 53,880,894.48 |
| 管理费用 | 141,936,826.33 | 53,909,305.18 | 208,097,636.28 | 143,402,950.83 |
| 研发费用 | 71,974,789.24 | 35,007,637.12 | 151,202,062.29 | 106,926,023.27 |
| 财务费用 | 39,106,155.52 | 19,518,868.3 | 43,665,234.73 | 28,441,068.38 |
| 其中:利息费用 | 25,774,812.94 | 12,578,515.79 | 43,832,449.16 | 40,909,503.65 |
| 其中:利息收入 | 2,088,288.21 | 703,994.14 | 6,789,828.07 | 14,666,944.8 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -219,832.95 | -145,833.92 | - | - |
| 加:投资收益 | 1,791,510.63 | -137,126.78 | -915,414.66 | -1,617,499.62 |
| 资产处置收益 | -15,766.35 | -14,282.22 | 122,573.32 | -52,710.21 |
| 资产减值损失(新) | -5,155,592.62 | -751,395.34 | -13,732,484.87 | -7,955,941.48 |
| 信用减值损失(新) | -1,111,571.92 | 97,615.4 | -397,538.69 | -540,095.35 |
| 其他收益 | 10,799,720.03 | 4,479,091.41 | 26,900,936.54 | 13,254,394.92 |
| 四、营业利润 | 96,556,973.65 | 38,412,949.18 | 129,653,437.59 | 174,450,674.85 |
| 加:营业外收入 | 83,664.98 | 52,117.94 | 677,071.69 | 359,622.1 |
| 减:营业外支出 | 3,453,431.47 | 2,560,478.62 | 4,773,434.29 | 3,482,230.44 |
| 五、利润总额 | 93,187,207.16 | 35,904,588.5 | 125,557,074.99 | 171,328,066.51 |
| 减:所得税费用 | 5,512,553.32 | -1,621,207.27 | 1,695,838.81 | 11,903,333.69 |
| 六、净利润 | 87,674,653.84 | 37,525,795.77 | 123,861,236.18 | 159,424,732.82 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 87,674,653.84 | 37,525,795.77 | 123,861,236.18 | 159,424,732.82 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 100,857,715.71 | 42,097,335.31 | 132,412,138.67 | 167,621,536.75 |
| 少数股东损益 | -13,183,061.87 | -4,571,539.54 | -8,550,902.49 | -8,196,803.93 |
| 扣除非经常损益后的净利润 | 96,405,475.88 | 42,125,323.02 | 119,526,907.04 | 166,963,572.61 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.17 | 0.53 | 0.67 |
| (二)稀释每股收益 | 0.4 | 0.17 | 0.53 | 0.67 |
| 八、其他综合收益 | -1,252,503.25 | -532,923.39 | -532,114.32 | -253,721.72 |
| 归属于母公司股东的其他综合收益 | -1,252,503.25 | -532,923.39 | -532,114.32 | -253,721.72 |
| 九、综合收益总额 | 86,422,150.59 | 36,992,872.38 | 123,329,121.86 | 159,171,011.1 |
| 归属于母公司股东的综合收益总额 | 99,605,212.46 | 41,564,411.92 | 131,880,024.35 | 167,367,815.03 |
| 归属于少数股东的综合收益总额 | -13,183,061.87 | -4,571,539.54 | -8,550,902.49 | -8,196,803.93 |
| 公告日期 | 2026-08-25 | 2026-04-23 | 2026-03-18 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |